Alena Skrahina

5 ta ish

Republican Scientific and Practical Centre of Pulmonology and Tuberculosis

1. Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis

   Giovanni Sotgiu, Simon Tiberi, Lia D’Ambrosio +18

   BoshqaOAOchiq kirish20163 iqtibos

   ABIABI:AkademIndex/2026.other.027997

2. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis

   Federica Fregonese, Shama D. Ahuja, Onno W. Akkerman +55

   Sharh maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.386597

3. The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbekistan

   Animesh A. Sinha, Robert J. Klebe, Michael L. Rekart +22

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyClinical Infectious Diseases20251 iqtibos

   ABIABI:AkademIndex/2025.article.000230

4. Effectiveness and Safety of Modified Fully Oral Nine-Month Treatment Regimens for Rifampicin-Resistant Tuberculosis: Prospective Cohort Study

   Oleksandr Korotych, Jay Achar, Elmira Gurbanova +23

   PreprintOAOchiq kirishTuberculosis Research and EpidemiologySSRN Electronic Journal20240 iqtibos

   ABIABI:AkademIndex/2024.preprint.000046

5. Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysis

   Anthony J. Garcia‐Prats, Maria Garcia‐Cremades, Vivian Cox +97

   Sharh maqolaOAOchiq kirishTuberculosis Research and EpidemiologyThe Lancet Child & Adolescent Health20250 iqtibos

   ABIABI:AkademIndex/2025.review-article.000036